SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation ...

BofA Securities recently downgraded PROCEPT BioRobotics from Buy to Neutral, citing slowing utilization growth and moderating system sales for its Aquablation technology amid tighter hospital capital ...

Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024 U.S. handpiece and consumables revenue of $43.1 million for the second ...

エレクトロニクス分野における多種多様なアプリケーションに半導体を提供する 世界的半導体メーカーのSTマイクロエレクトロニクス（NYSE：STM、以下ST）と、 先進的ロボット工学の権威であり、イタリアで最も有名な大学の1校である 聖アンナ大学院大学 ...

Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company’s strong revenue and install ...

Procept BioRobotics saw a revenue beat in the first quarter, surpassing expectations with approximately a 6% overall increase, including a 3% beat in the United States and a significant 29% beat ...

InvestingPro Insights Procept Biorobotics Corporation's (PRCT) recent all-time high is further contextualized by InvestingPro data, which reveals a staggering 163.59% price total return over the past ...